Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis

키워드

참고문헌 (25)

1. Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
2. Chaft JE, "Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib : implications for clinical trial design", Clin Cancer Res, 17, pp.6298~6303 (2011)
3. Conforti F, "EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung", Lung Cancer, 81, pp.440~444 (2013)
4. Nishie K, "Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease : a retrospective analysis for Japanese patients with activating EGFR mutations", J Thorac Oncol, 7, pp.1722~1727 (2012)
5. Yang JJ, "Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer", Lung Cancer, 79, pp.33~39 (2013)
6. Coleman RE., "Skeletal complications of malignancy", Cancer, 80(8 Suppl), pp.1588~1594 (1997)
7. Coleman RE, "Metastatic bone disease : clinical features, pathophysiology and treatment strategies", Cancer Treat Rev, 27, pp.165~176 (2001)
8. Bury T, "Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer", Eur J Nucl Med, 25, pp.1244~1247 (1998)
9. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
10. Choi HS, "Role of (1)(8)F-FDG PET", CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients, 2014, pp.38, 109~114
11. Costelloe CM, "Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST", J Cancer, 1, pp.80~92 (2010)
12. Chao HS, "Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib", Clin Nucl Med, 34, pp.346~349 (2009)
13. Hendriks LE, "EGFR mutated non-small cell lung cancer patients : more prone to development of bone and brain metastases?", Lung Cancer, 84, pp.86~91 (2014)
14. Scagliotti GV, "Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid : subgroup analysis from a randomized phase 3 study", J Thorac Oncol, 7, pp.1823~1829 (2012)
15. Normanno N, "Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases : different mechanisms of action for a novel therapeutic application?", Endocr Relat Cancer, 13, pp.3~6 (2006)
16. Inomata M, "Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer", Anticancer Res, 31, pp.4519~4523 (2011)
17. Nishino M, "Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy : developing criteria to continue therapy beyond RECIST progression", Cancer, 119, pp.3761~3768 (2013)
18. Nishino M, "Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors", Lung Cancer, 79, pp.283~288 (2013)
19. Asami K, "Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations", Lung Cancer, 79, pp.276~282 (2013)
20. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
21. Li W, "T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients", Lung Cancer, 84, pp.295~300 (2014)
22. Arcila ME, "Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay", Clin Cancer Res, 17, pp.1169~1180 (2011)
23. Oxnard GR, "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA", Clin Cancer Res, 20, pp.1698~1705 (2014)
24. Wang Z, "Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC", PLoS One, 9, pp.110780~ (2014)
25. Lecouvet FE, "Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques : a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group", Eur J Cancer, 50, pp.2519~2531 (2014)

관련 논문AI추천